207 related articles for article (PubMed ID: 27509020)
1. Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients.
Sung C; Wei Y; Watanabe S; Lee HS; Khoo YM; Fan L; Rathore AP; Chan KW; Choy MM; Kamaraj US; Sessions OM; Aw P; de Sessions PF; Lee B; Connolly JE; Hibberd ML; Vijaykrishna D; Wijaya L; Ooi EE; Low JG; Vasudevan SG
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004851. PubMed ID: 27509020
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial.
Low JG; Sung C; Wijaya L; Wei Y; Rathore APS; Watanabe S; Tan BH; Toh L; Chua LT; Hou Y; Chow A; Howe S; Chan WK; Tan KH; Chung JS; Cherng BP; Lye DC; Tambayah PA; Ng LC; Connolly J; Hibberd ML; Leo YS; Cheung YB; Ooi EE; Vasudevan SG
Lancet Infect Dis; 2014 Aug; 14(8):706-715. PubMed ID: 24877997
[TBL] [Abstract][Full Text] [Related]
3. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial.
Watanabe S; Rathore AP; Sung C; Lu F; Khoo YM; Connolly J; Low J; Ooi EE; Lee HS; Vasudevan SG
Antiviral Res; 2012 Oct; 96(1):32-5. PubMed ID: 22867971
[TBL] [Abstract][Full Text] [Related]
4. Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy.
Watanabe S; Chan KW; Dow G; Ooi EE; Low JG; Vasudevan SG
Antiviral Res; 2016 Mar; 127():10-9. PubMed ID: 26794905
[TBL] [Abstract][Full Text] [Related]
5. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model.
Rathore AP; Paradkar PN; Watanabe S; Tan KH; Sung C; Connolly JE; Low J; Ooi EE; Vasudevan SG
Antiviral Res; 2011 Dec; 92(3):453-60. PubMed ID: 22020302
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients.
Nguyen NM; Tran CN; Phung LK; Duong KT; Huynh Hle A; Farrar J; Nguyen QT; Tran HT; Nguyen CV; Merson L; Hoang LT; Hibberd ML; Aw PP; Wilm A; Nagarajan N; Nguyen DT; Pham MP; Nguyen TT; Javanbakht H; Klumpp K; Hammond J; Petric R; Wolbers M; Nguyen CT; Simmons CP
J Infect Dis; 2013 May; 207(9):1442-50. PubMed ID: 22807519
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Antiviral Testing for Dengue Virus Infection in Mouse Models and Its Association with Clinical Studies.
Watanabe S; Low JG; Vasudevan SG
ACS Infect Dis; 2018 Jul; 4(7):1048-1057. PubMed ID: 29756760
[TBL] [Abstract][Full Text] [Related]
8. Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys.
Farias KJ; Machado PR; Muniz JA; Imbeloni AA; da Fonseca BA
Viral Immunol; 2015 Apr; 28(3):161-9. PubMed ID: 25664975
[TBL] [Abstract][Full Text] [Related]
9. A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction.
Kaptein SJF; Goethals O; Kiemel D; Marchand A; Kesteleyn B; Bonfanti JF; Bardiot D; Stoops B; Jonckers THM; Dallmeier K; Geluykens P; Thys K; Crabbe M; Chatel-Chaix L; Münster M; Querat G; Touret F; de Lamballerie X; Raboisson P; Simmen K; Chaltin P; Bartenschlager R; Van Loock M; Neyts J
Nature; 2021 Oct; 598(7881):504-509. PubMed ID: 34616043
[TBL] [Abstract][Full Text] [Related]
10. Isolation of dengue virus serotype 4 genotype II from a patient with high viral load and a mixed Th1/Th17 inflammatory cytokine profile in South Brazil.
Kuczera D; Bavia L; Mosimann AL; Koishi AC; Mazzarotto GA; Aoki MN; Mansano AM; Tomeleri EI; Costa Junior WL; Miranda MM; Lo Sarzi M; Pavanelli WR; Conchon-Costa I; Duarte Dos Santos CN; Bordignon J
Virol J; 2016 Jun; 13():93. PubMed ID: 27267473
[TBL] [Abstract][Full Text] [Related]
11. Dengue Virus Evolution under a Host-Targeted Antiviral.
Plummer E; Buck MD; Sanchez M; Greenbaum JA; Turner J; Grewal R; Klose B; Sampath A; Warfield KL; Peters B; Ramstedt U; Shresta S
J Virol; 2015 May; 89(10):5592-601. PubMed ID: 25762732
[TBL] [Abstract][Full Text] [Related]
12. Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys.
Ajariyakhajorn C; Mammen MP; Endy TP; Gettayacamin M; Nisalak A; Nimmannitya S; Libraty DH
Antimicrob Agents Chemother; 2005 Nov; 49(11):4508-14. PubMed ID: 16251289
[TBL] [Abstract][Full Text] [Related]
13. Ten years of dengue drug discovery: progress and prospects.
Lim SP; Wang QY; Noble CG; Chen YL; Dong H; Zou B; Yokokawa F; Nilar S; Smith P; Beer D; Lescar J; Shi PY
Antiviral Res; 2013 Nov; 100(2):500-19. PubMed ID: 24076358
[TBL] [Abstract][Full Text] [Related]
14. Luteolin restricts dengue virus replication through inhibition of the proprotein convertase furin.
Peng M; Watanabe S; Chan KWK; He Q; Zhao Y; Zhang Z; Lai X; Luo D; Vasudevan SG; Li G
Antiviral Res; 2017 Jul; 143():176-185. PubMed ID: 28389141
[TBL] [Abstract][Full Text] [Related]
15. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs.
Schul W; Liu W; Xu HY; Flamand M; Vasudevan SG
J Infect Dis; 2007 Mar; 195(5):665-74. PubMed ID: 17262707
[TBL] [Abstract][Full Text] [Related]
16. A novel inhibitor of dengue virus replication that targets the capsid protein.
Byrd CM; Dai D; Grosenbach DW; Berhanu A; Jones KF; Cardwell KB; Schneider C; Wineinger KA; Page JM; Harver C; Stavale E; Tyavanagimatt S; Stone MA; Bartenschlager R; Scaturro P; Hruby DE; Jordan R
Antimicrob Agents Chemother; 2013 Jan; 57(1):15-25. PubMed ID: 23070172
[TBL] [Abstract][Full Text] [Related]
17. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
DeVincenzo JP; McClure MW; Symons JA; Fathi H; Westland C; Chanda S; Lambkin-Williams R; Smith P; Zhang Q; Beigelman L; Blatt LM; Fry J
N Engl J Med; 2015 Nov; 373(21):2048-58. PubMed ID: 26580997
[TBL] [Abstract][Full Text] [Related]
18. A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity.
Moshiri J; Constant DA; Liu B; Mateo R; Kearnes S; Novick P; Prasad R; Nagamine C; Pande V; Kirkegaard K
mBio; 2020 Nov; 11(6):. PubMed ID: 33173007
[TBL] [Abstract][Full Text] [Related]
19. Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir.
Chen YL; Abdul Ghafar N; Karuna R; Fu Y; Lim SP; Schul W; Gu F; Herve M; Yokohama F; Wang G; Cerny D; Fink K; Blasco F; Shi PY
J Virol; 2014 Feb; 88(3):1740-7. PubMed ID: 24257621
[TBL] [Abstract][Full Text] [Related]
20. Drug repurposing of minocycline against dengue virus infection.
Leela SL; Srisawat C; Sreekanth GP; Noisakran S; Yenchitsomanus PT; Limjindaporn T
Biochem Biophys Res Commun; 2016 Sep; 478(1):410-416. PubMed ID: 27396621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
